ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2091

Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus

Goh Murayama1, Asako Chiba2, Atsushi Nomura3, Hirofumi Amano1, Ken Yamaji1, Naoto Tamura1 and Sachiko Miyake4,5, 1Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, 3JUNTENDO UNIVERSITY SCHOOL OF MEDICINE, Tokyo, Japan, 4Division of Immunology/NCNP, Natl Institute of Neuroscience, Kodaira Tokyo, Japan, 5Immunology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: innate immunity, Nephritis and treatment, SLE, T cells

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain: Vα7.2-Jα33 in humans and Vα19-Jα33 in mice. Previously, we reported that MAIT cells are activated in patients with systemic lupus erythematosus (SLE) and that the activation state of these cells correlated with disease activity. By using MR1 deficient mice lacking MAIT cells, we revealed that MAIT cells contribute to the disease severity of lupus in FcγRIIB-/- Yaa mice. In this study, we asked how MAIT cells are involved in the pathogenesis in this lupus model and explored their potential as a therapeutic target for lupus. We also investigated whether MAIT cells infiltrate in the nephritic kidneys of lupus patients.

Methods:

FcγRIIB-/- Yaa mice were crossed to MR1 deficient mice lacking MAIT cells, and disease progression was compared between MR1-/- and MR1+/+ FcγRIIB-/- Yaa mice. The levels of serum anti-dsDNA antibody and urinary albumin were measured. The severity of nephritis was assessed histologically. T and B cell subsets in the spleen and kidneys at 2 months of age were analyzed by using flow cytometry. FcγRIIb-/- Yaa mice were treated with a suppressive MR1 ligand(MR1L) orally three times weekly for 4 weeks starting at 4 weeks of age. Infiltration of MAIT cells was assessed in kidney biopsy specimens from lupus patients using a confocal microscope.

Results:

MAIT cell deficiency improved the disease course of lupus in FcγRIIb-/- Yaa mice as shown by the increased survival rate, reduced serum anti-dsDNA antibody levels, glomerulonephritis scores and IgG and C3 deposition in glomeruli in MR1-/- FcγRIIB-/- Yaa mice. MAIT cells enhanced germinal center reaction which was accompanied by the increase of T follicular helper cells, germinal center B and plasma cells and the reduction of T regulatory and T follicular regulatory cells. The presence of MAIT cells enhanced cytokine producing capacity of T and innate-T cells in the spleen and kidneys. Activated MAIT cells were accumulated in the kidneys and produced inflammatory cytokines. Administration of MR1L decreased serum anti-ds DNA antibody levels and reduced germinal center B and plasma cells. The deposition of IgG and C3 in the glomeruli was also reduce in FcγRIIb-/- Yaa mice treated with MR1L. MAIT cells were accumulated in the nephritic kidneys of lupus patients.

Conclusion:

MAIT cells exacerbated the disease severity of lupus by enhancing autoantibody production and tissue inflammation in FcγRIIb-/- Yaa mice. MAIT cells were found in the nephritic kidneys of lupus patients, suggesting these cells may also contribute to lupus pathogenesis in human patients. As administration of MR1L suppressed the disease course of lupus, MAIT cells hold potential as a new therapeutic target for SLE.


Disclosure: G. Murayama, None; A. Chiba, CeUGAI PHARMACEUTICAL CO., LTD, 8; A. Nomura, None; H. Amano, None; K. Yamaji, None; N. Tamura, Chugai Parmaceutical Co., LTD, 2,Astellas Pharma Inc., 2,ASAHI KASEI MEDICAL, 2,Sanofi K.K., 8,Bristol-Myers Squibb, 8; S. Miyake, TAIHO PHARMACEUTICAL CO., LTD., 5,Chugai Parmaceutical Co., LTD, 8,Astellas Pharma Inc., 8,Bristol-Myers Squibb, 8,Sanofi K.K., 8,Pfizer, Inc., 8,AYUMI Pharmaceutical Co., LTD, 8.

To cite this abstract in AMA style:

Murayama G, Chiba A, Nomura A, Amano H, Yamaji K, Tamura N, Miyake S. Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/mucosal-associated-invariant-t-mait-cells-as-a-potential-therapeutic-target-for-systemic-lupus-erythematosus/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mucosal-associated-invariant-t-mait-cells-as-a-potential-therapeutic-target-for-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.